Rams finally ran the ball well in New Orleans, and it kept them in the playoff race
Pep Guardiola has pledged to step aside if he fails to turn around Manchester City’s poor run of form. The City boss is enduring the worst run of his glittering managerial career after a six-game winless streak featuring five successive defeats and a calamitous 3-3 draw in a match his side had led 3-0. The 53-year-old, who has won 18 trophies since taking charge at the Etihad Stadium in 2016, signed a contract extension through to the summer of 2027 just over a week ago. Yet, despite his remarkable successes, he still considers himself vulnerable to the sack and has pleaded with the club to keep faith. “I don’t want to stay in the place if I feel like I’m a problem,” said the Spaniard, who watched in obvious frustration as City conceded three times in the last 15 minutes in a dramatic capitulation against Feyenoord in midweek. “I don’t want to stay here just because the contract is there. “My chairman knows it. I said to him, ‘Give me the chance to try come back’, and especially when everybody comes back (from injury) and see what happens. “After, if I’m not able to do it, we have to change because, of course, (the past) nine years are dead. “More than ever I ask to my hierarchy, give me the chance. “Will it be easy for me now? No. I have the feeling that still I have a job to do and I want to do it.” City have been hampered by a raft of injuries this term, most pertinently to midfield talisman and Ballon d’Or winner Rodri. The Euro 2024 winner is expected to miss the remainder of the season and his absence has been keenly felt over the past two months. Playmaker Kevin De Bruyne has also not started a match since September. The pressure continues to build with champions City facing a crucial trip to title rivals and Premier League leaders Liverpool on Sunday. Defeat would leave City trailing Arne Slot’s side by 11 points. “I don’t enjoy it at all, I don’t like it,” said Guardiola of his side’s current situation. “I sleep not as good as I slept when I won every game. “The sound, the smell, the perfume is not good enough right now. “But I’m the same person who won the four Premier Leagues in a row. I was happier because I ate better, lived better, but I was not thinking differently from who I am.” Guardiola is confident his side will not stop battling as they bid to get back on track. He said: “The people say, ‘Yeah, it’s the end of that’. Maybe, but we are in November. We will see what happens until the end. “What can you do? Cry for that? You don’t stay long – many, many years without fighting. That is what you try to look for, this is the best (way). “Why should we not believe? Why should it not happen with us?”
Qatar tribune agencies Manila An impeachment complaint was filed on Monday against Philippine Vice President Sara Duterte on allegations of corruption, breach of public trust and other constitutional violations. The complaint - the first against a vice president in the Philippines - was filed in the House of Representatives by a group of civil society leaders, former government officials and sectoral representatives, including a family member of a victim of the controversial war on drugs unleashed by the vice president’s father, former president Rodrigo Duterte. “The vice president has reduced public office to a platform for violent rhetoric, personal enrichment, elitist entitlement and a shield for impunity,” said Teresita Quintos Deles, a former government official and one of the complainants. “Her actions desecrate our institutions, and her continued grip on power insults every Filipino who stands for good governance and the rule of law,” she added. The complaint was endorsed by left-wing Akbayan party representative Perci Cendeña, who said: “We cannot allow public office to be weaponized for corruption, violence and betrayal of trust. The Filipino people deserve leaders who serve with integrity, not rulers who exploit power for personal gain.” Duterte did not immediately issue any response to the impeachment bid, which accused her of about two dozen alleged crimes. The impeachment complaint was filed more than one week after Duterte threatened to have President Ferdinand Marcos Jr, the first lady and the House speaker assassinated if she herself was killed. The threat came amid an investigation on the alleged misuse of 612.5 million pesos ($10.4 million) worth of funds of the Department of Education. Vice President Duterte resigned from her post as education secretary in Marcos’ Cabinet in June, indicating a crack in the political alliance that propelled the duo to a clear victory in 2022. The impeachment complaint will be scrutinized by the Philippine Congress, which is dominated by allies of Marcos and his cousin and key backer, Romualdez, who also has been politically at odds with the vice president. Copy 03/12/2024 10
NEW YORK (AP) — Lawyers for tried for a third time Friday to persuade a judge to let him leave jail while he awaits his but a decision won’t come until next week. Judge Arun Subramanian said at a hearing that he will release his decision on Combs’ latest request for bail after Combs’ lawyers and federal prosecutors file letters addressing outstanding issues. Those letters are due at noon on Monday, Subramanian said. Combs’ lawyers pitched having him await trial under around-the-clock surveillance either his mansion on an island near Miami Beach or — after the judge scoffed at that location — an apartment on Manhattan’s Upper East Side. Their plan essentially amounts to putting Combs on house arrest, with strict limits on who he has contact with. But prosecutors argue that Combs has routinely flouted jail rules and can’t be trusted not to interfere with witnesses or the judicial process. “The argument that he’s a lawless person who doesn’t follow instructions isn’t factually accurate,” Combs lawyer Anthony Ricco argued. “The idea that he’s an out-of-control individual who has to be detained isn’t factually accurate.” Combs, 55, has pleaded not guilty to for years with help from a network of associates and employees while silencing victims through blackmail and violence, including kidnapping, arson and physical beatings. His trial is slated to begin May 5. The Bad Boy Records founder remains locked up at a where he spent his Nov. 4 birthday. Two other judges that Combs would be a danger to the community if he is released and an appeals court judge last month denied Combs’ immediate release while a three-judge panel of the 2nd U.S. Circuit Court of Appeals weighs his bail request. Friday’s hearing was the second time Combs was in court this week. On Tuesday, a judge from using as evidence papers that were seized from his cell during jail-wide sweep for contraband and weapons at the Metropolitan Detention Center in Brooklyn. As he entered through a side door, Combs waved to relatives including his mother and several of his children in the courtroom gallery, tapping his hand to his heart and blowing kisses at them. He then hugged his lead attorney, Marc Agnifilo, before taking a seat at the defense table. He was not handcuffed or shackled and wore a beige jail uniform, occasionally pulling a pair of reading glasses from his pocket as he peered at papers in front of him. Prosecutors maintain that no bail conditions will mitigate the “risk of obstruction and dangerousness to others” of releasing Combs from jail. Prosecutors contend that while locked up the “I’ll Be Missing You” artist has orchestrated social media campaigns aimed at tainting the jury pool. They allege that he has also attempted to publicly leak materials he thinks would be helpful to his case and is contacting potential witnesses via third parties. “Simply put, the defendant cannot be trusted,” Assistant U.S. Attorney Christy Slavik argued. Combs’ lawyer Teny Geragos countered that, given the strict release conditions proposed, “it would be impossible for him not to follow rules.”
TAMPA, Fla. (AP) — Jake Evans scored for the career-high fifth consecutive game and the surging Montreal Canadiens beat the Tampa Bay Lightning 5-2 on Sunday night. Christian Dvorak, Joel Armia, Brendan Gallagher and Alex Newhook also scored to help the Canadiens win for the fifth time in six games. Sam Montembeault made 21 saves. Nikita Kucherov and Brandon Hagel scored for Tampa Bay. Jonas Johansson stopped 31 shots. Newhook opened the scoring on a one-timer midway through the first period. Hagel tied it 37 seconds into the second period, but Dvorak and Evans scored 5:54 apart in the period for a two-goal Montreal lead they would not relinquish. SABRES 4, BLUES 2 ST. LOUIS (AP) — Jason Zucker scored a tiebreaking power-play goal with 9:30 remaining and Buffalo notched their third straight victory by beating St. Louis. Jiri Kulich extended Buffalo’s lead with a breakaway goal that went between Blues goalie Jordan Binnington’s legs with 3:41 to play. Tage Thompson had a goal and an assist against his former team as the Sabres won in St. Louis for just the second time in 12 years to sweep the season series. Zucker had a goal and an assist, and Jack Quinn had two assists for Buffalo. Ukko-Pekka Luukkonen stopped 35 shots. Brayden Schenn and Nathan Walker scored for the Blues. Binnington had 12 saves. Buffalo scored on two of its first three shots, including its first of the game. DUCKS 5, OILERS 3 ANAHEIM, Calif. (AP) — Ryan Strome scored with 2:36 remaining as Anaheim rallied from a two-goal deficit in the second period to defeat Edmonton. Strome’s goal, his sixth of the season, originally wasn’t called, but it was reversed after a review. Strome’s shot was entirely over the goal line before Edmonton goalie Calvin Pickard could stop it with his skate. Mason McTavish added an empty-net goal. It is the first time since March 30, 2019, the Ducks have defeated the Oilers by more than one goal. Cutter Gauthier, McTavish and Robby Fabbri each had a goal and an assist. Drew Helleson also scored for Anaheim, which snapped a seven-game losing streak to Edmonton. Lukas Dostal made 20 saves. Leon Draisaitl had two goals and Connor McDavid two assists for the Oilers, who were 3-0-1 in their past four. Evan Bouchard also tallied a goal and Pickard stopped 27 shots. RED WINGS 4, CAPITALS 2 DETROIT (AP) — Patrick Kane reached the 1,300-point mark and Todd McLellan won for the first time as Detroit’s coach in their victory over Washington. Kane, who needed two points to reach that mark, had a power-play goal and assist during Detroit’s four-goal first period. Alex DeBrincat scored two goals and Lucas Raymond added another as the Red Wings snapped a four-game losing streak. Alex Lyon made 26 saves. McLellan replaced Derek Lalonde prior to Friday’s loss to Toronto . Alex Ovechkin scored for the second consecutive game after missing the previous 16 due to a fractured fibula . The Capitals star forward is 25 goals shy of passing Wayne Gretzky’s NHL record of 894 . Nic Dowd had the other Capitals goal. Charlie Lindgren made 23 saves but Washington remained one point behind first-place New Jersey in the Eastern Conference. PENGUINS 3, ISLANDERS 2 PITTSBURGH (AP) — Sidney Crosby broke Mario Lemieux’s Pittsburgh franchise career record for assists on Michael Bunting’s power-play goal and the Penguins beat New York. Crosby has 1,034 assists, good for 12th in NHL history. Only three players — Ray Bourque, Wayne Gretzky and Steve Yzerman — have more assists with a single team. The 37-year-old Crosby has played 1,310-regular-season games. Lemieux played 915. Evgeni Malkin added the deciding power-play goal in the third for Pittsburgh, which has 14 goals with the man advantage in its last 13 games. Anthony Beauvillier also scored to help the Penguins win for the seventh time in their last eight home games. Alex Nedeljkovic made 29 saves in his first start since Dec. 17. Kris Letang missed the game because of a lower-body injury, and defenseman Nathan Clurman made his NHL debut. Anders Lee and Bo Horvat scored third-period goals for the Islanders, who fell behind 3-0 before their rally fell short. Marcus Hogberg stopped 38 shots during his first start since April 28, 2021. GOLDEN KNIGHTS 3, FLAMES 0 LAS VEGAS (AP) — Brett Howden scored his 15th goal of the season and Ilya Samsonov stopped 31 shots as Vegas Golden defeated Calgary. Howden redirected defenseman Alex Pietrangelo’s shot from the top of the slot late in the second period and is now tied with Ivan Barbashev for the team lead in goals. Howden has scored a goal in four of the last five games. Victor Olofsson and Tanner Pearson also scored for the Golden Knights, who have shut out Calgary twice this season, beating them 5-0 on Oct. 28 . Dan Vladar made 34 saves for Calgary. The Golden Knights have now won six straight, the longest active win streak in the NHL, while improving to 25-8-3 on the year. They own a 13-2-1 record against Pacific Division opponents. SENATORS 3, WILD 1 ST. PAUL, Minn. (AP) — Josh Norris broke a tie on a power play with 7:18 left, Leevi Merilainen made 30 saves in his fifth NHL game and Ottawa beat Minnesota. Ottawa has won seven of its past nine games, while the Wild have lost five of their past seven. The Senators won in Minnesota for the first time since 2016. With starter Linus Ullmark and backup Anton Forsberg out with injuries, the Senators have been relying on Merilainen and Mads Sogaard since before the NHL holiday break. Frederick Gaudreau opened the scoring for Minnesota late in the first period. Ridly Greig tied it early in the second. Claude Giroux added an empty-netter. STARS 5, BLACKHAWKS 1 CHICAGO (AP) — Matt Duchene and Jamie Benn each had a goal and two assists, and Dallas beat Chicago. Jason Robertson, Evgenii Dadonov and Wyatt Johnston each had a goal and an assist for Dallas, which had lost three of four. Jake Oettinger made 24 saves. Chicago dropped its fourth consecutive game. It lost three of four in its season series against Dallas. Connor Bedard scored his 10th goal for the Blackhawks, and Arvid Soderblom made 26 stops. Next up for Bedard and company is the Winter Classic on Tuesday against St. Louis. Dallas grabbed control after Chicago forward Tyler Bertuzzi was ejected 8:11 into the second period. Bertuzzi was sent off for elbowing Stars forward Colin Blackwell in the face.
THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE AmgenFollowed poll processes transparently, will review all legitimate concerns: EC to Cong
Pep Guardiola: If I can’t reverse Manchester City slide then I have to go
ith a population of 284 million, Indonesia is one of the largest and most promising markets globally. Google's Southeast Asia economy report highlights the archipelago as Southeast Asia's most prominent digital economy, boasting a gross merchandise value (GMV) of US$82 billion in 2023. E-commerce alone is expected to grow at a compound annual growth rate (CAGR) of 15 percent, reaching $82 billion by 2025. While many startups have risen and grown in Indonesia, making it the Southeast Asian country with the second highest venture capital investment after Singapore, international players have also been aggressively eyeing the market. In e-commerce and ride-sharing, prominent international players like Shopee, Lazada and Grab have been competing with local heroes such as GoTo, Tokopedia and Blibli while expanding their reach. However, with profitability as the new focus in the wake of the latest global economic changes, these tech unicorns have moved away from merely growing market shares to maintaining sustainable and profitable growth. GoTo is a classic example. The local unicorn expanded into markets such as Vietnam and Singapore at the peak of its growth. However, it announced its exit from Vietnam in September, with reports also suggesting that the tech giant may soon exit Singapore, while other companies such as Grab and SEA have earlier undertaken their restructuring efforts. Nonetheless, with a current internet business penetration that is still far below developed markets like the United States and China, much of the Indonesian market remains underpenetrated. Large portions of the Indonesian archipelago are still out of reach for many of these companies due to logistical challenges. Whether you're looking to broaden your horizons or stay informed on the latest developments, "Viewpoint" is the perfect source for anyone seeking to engage with the issues that matter most. By registering, you agree with 's Please check your email for your newsletter subscription. Those who successfully convert these challenges into opportunities can win this market.
Friendly reminder |
The authenticity of this information has not been verified by this website and is for your reference only. Please do not reprint without permission. If authorized by this website, it should be used within the scope of authorization and marked with "Source: this website". |
Special attention |
Some articles on this website are reprinted from other media. The purpose of reprinting is to convey more industry information, which does not mean that this website agrees with their views and is responsible for their authenticity. Those who make comments on this website forum are responsible for their own content. This website has the right to reprint or quote on the website. The comments on the forum do not represent the views of this website. If you need to use the information provided by this website, please contact the original author. The copyright belongs to the original author. If you need to contact this website regarding copyright, please do so within 15 days. |